{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:02:35Z","timestamp":1789776155796,"version":"4.0.1"},"reference-count":11,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the efficacy, safety, and patient satisfaction of bepotastine besilate 1.5% versus sodium cromoglycate 4% eye drops in the management of chronic allergic conjunctivitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this prospective, double-masked comparative study, 100 adult patients with chronic allergic conjunctivitis were assigned to receive either bepotastine twice daily (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 50) or cromolyn 4 times daily (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 50) for 6 months. The primary outcome was the change in ocular itching severity on a standardized 0\u20133 scale. Secondary outcomes included changes in redness, tearing, swelling, discomfort, treatment compliance, adverse events, and patient satisfaction. Assessments were conducted at baseline, 2 weeks, 6 weeks, 3 months, and 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Both treatments significantly improved symptoms from baseline after 6 months. Bepotastine showed superior reduction in ocular itching severity (74.4% improvement) compared to cromolyn (63.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Cromolyn was more effective in reducing conjunctival redness (70.0% vs. 59.3%). Bepotastine also showed numerical advantages in tearing, swelling, and discomfort relief. Adverse events were mild and comparable, with slightly more burning sensation reported in the cromolyn group. Compliance and patient satisfaction were higher in the bepotastine group, attributed to its convenient twice-daily dosing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Both bepotastine besilate and sodium cromoglycate are effective and safe for chronic allergic conjunctivitis. Bepotastine offers faster relief of itching and greater convenience, whereas cromolyn provides better control of conjunctival redness. Treatment choice should be individualized based on symptom profile and patient preferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261457779","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:28:56Z","timestamp":1781098136000},"page":"602-608","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Topical Bepotastine Besilate 1.5% Versus Sodium Cromoglycate 4% in Chronic Allergic Conjunctivitis: A Prospective Study"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-3213","authenticated-orcid":false,"given":"Mayank","family":"Jhanwar","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, INHS Sanjivani, Kochi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Military Hospital, Bareilly, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nathan","sequence":"additional","affiliation":[{"name":"Department of Medicine, INHS Sanjivani, Kochi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"8","key":"e_1_3_2_2_1","first-page":"e89928","article-title":"Prevalence of asthma and allergic rhinitis and their association with chronotype among adolescents in Ernakulam district: A school-based cross-sectional study","volume":"17","author":"Sureshkumar P","year":"2025","unstructured":"1.Sureshkumar P, , Mohandas S, , Rose B, et al. Prevalence of asthma and allergic rhinitis and their association with chronotype among adolescents in Ernakulam district: A school-based cross-sectional study. Cureus 2025;17(8):e89928.","journal-title":"Cureus"},{"issue":"11","key":"e_1_3_2_3_1","first-page":"915","article-title":"Topical antihistamines and mast cell stabilizers for treating allergic conjunctivitis","volume":"93","author":"Mounsey AL","year":"2016","unstructured":"2.Mounsey AL, , Gray RE. Topical antihistamines and mast cell stabilizers for treating allergic conjunctivitis. Am Fam Physician 2016;93(11):915\u2013916.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2016.1158282"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijceo.2024.003"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S66637"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000473"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.09.005"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1346085"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(02)80060-1"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2011.09.004"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S431889"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261457779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261457779","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261457779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:17:28Z","timestamp":1789773448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261457779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10807683261457779"],"URL":"https:\/\/doi.org\/10.1177\/10807683261457779","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}